Robert M Rifkin1, Sundar Jagannath2, Brian G M Durie3, Mohit Narang4, Howard R Terebelo5, Cristina J Gasparetto6, Kathleen Toomey7, James W Hardin8, Lynne Wagner9, Kejal Parikh10, Safiya Abouzaid10, Shankar Srinivasan10, Amani Kitali10, Faiza Zafar10, Rafat Abonour11. 1. US Oncology Research, Rocky Mountain Cancer Centers, Denver, Colorado. Electronic address: robert.rifkin@usoncology.com. 2. Mount Sinai Hospital, New York, New York. 3. Cedars-Sinai Samuel Oschin Cancer Center, Los Angeles, California. 4. US Oncology Research, Maryland Oncology Hematology, Columbia, Maryland. 5. Providence Cancer Institute, Southfield, Michigan. 6. Duke University Medical Center, Durham, North Carolina. 7. Steeplechase Cancer Center, Somerville, New Jersey. 8. University of South Carolina, Columbia, South Carolina. 9. Wake Forest University School of Medicine, Winston-Salem, North Carolina. 10. Celgene Corporation, Summit, New Jersey. 11. Indiana University Simon Cancer Center, Indianapolis, Indiana.
Abstract
PURPOSE: Maintenance therapy after autologous stem cell transplantation (ASCT) improves clinical outcomes in multiple myeloma (MM), but the effect of continued treatment with lenalidomide-only maintenance, or any maintenance, on health care resource utilization (HCRU) is largely unknown. METHODS: Here we present an analysis of HCRU and clinical outcomes in a cohort of patients from the Connect MM registry, the largest, ongoing, observational, prospective US registry of patients with symptomatic newly diagnosed MM. In this study, patients with newly diagnosed MM who completed induction and single ASCT without subsequent consolidation received lenalidomide-only maintenance (n = 180), any maintenance (n = 256), or no maintenance (n = 165). HCRU (hospitalization, surgery/procedures, and concurrent medications [growth factors, bisphosphonates, or neuropathic pain medication]) was assessed starting from 100 days post-ASCT for up to 2 years. FINDINGS: Although the rates of hospitalization per 100 person-years were similar across groups at the end of years 1 and 2, the median duration of hospitalization was numerically longer with no maintenance. The rates of use of growth factors, bisphosphonates, and neuropathic pain medication were generally similar in all 3 groups. The receipt of any maintenance was associated with significantly reduced use of neuropathic pain medications during year 1. Of note, lenalidomide-only maintenance was associated with significantly longer progression-free survival (54.5 vs 30.4 months; hazard ratio [HR] = 0.58; 95% CI, 0.43-0.79; P = 0.0005) and overall survival (OS) (median OS not reached in either group; HR = 0.45; 95% CI, 0.28-0.73; P = 0.001) compared with no maintenance. Likewise, the group treated with any maintenance had significantly longer median progression-free survival (44.7 vs 30.4 months; HR = 0.62; 95% CI, 0.47-0.82; P = 0.0008) and OS (median OS not reached in either group; HR = 0.50; 95% CI, 0.33-0.76; P = 0.001) than did the group that did not receive maintenance. IMPLICATIONS: These findings suggest that in this largely community-based study population, post-ASCT maintenance therapy, including lenalidomide-only maintenance, improves clinical outcomes without negatively affecting HCRU. ClinicalTrials.gov identifier: NCT01081028.
PURPOSE: Maintenance therapy after autologous stem cell transplantation (ASCT) improves clinical outcomes in multiple myeloma (MM), but the effect of continued treatment with lenalidomide-only maintenance, or any maintenance, on health care resource utilization (HCRU) is largely unknown. METHODS: Here we present an analysis of HCRU and clinical outcomes in a cohort of patients from the Connect MM registry, the largest, ongoing, observational, prospective US registry of patients with symptomatic newly diagnosed MM. In this study, patients with newly diagnosed MM who completed induction and single ASCT without subsequent consolidation received lenalidomide-only maintenance (n = 180), any maintenance (n = 256), or no maintenance (n = 165). HCRU (hospitalization, surgery/procedures, and concurrent medications [growth factors, bisphosphonates, or neuropathic pain medication]) was assessed starting from 100 days post-ASCT for up to 2 years. FINDINGS: Although the rates of hospitalization per 100 person-years were similar across groups at the end of years 1 and 2, the median duration of hospitalization was numerically longer with no maintenance. The rates of use of growth factors, bisphosphonates, and neuropathic pain medication were generally similar in all 3 groups. The receipt of any maintenance was associated with significantly reduced use of neuropathic pain medications during year 1. Of note, lenalidomide-only maintenance was associated with significantly longer progression-free survival (54.5 vs 30.4 months; hazard ratio [HR] = 0.58; 95% CI, 0.43-0.79; P = 0.0005) and overall survival (OS) (median OS not reached in either group; HR = 0.45; 95% CI, 0.28-0.73; P = 0.001) compared with no maintenance. Likewise, the group treated with any maintenance had significantly longer median progression-free survival (44.7 vs 30.4 months; HR = 0.62; 95% CI, 0.47-0.82; P = 0.0008) and OS (median OS not reached in either group; HR = 0.50; 95% CI, 0.33-0.76; P = 0.001) than did the group that did not receive maintenance. IMPLICATIONS: These findings suggest that in this largely community-based study population, post-ASCT maintenance therapy, including lenalidomide-only maintenance, improves clinical outcomes without negatively affecting HCRU. ClinicalTrials.gov identifier: NCT01081028.
Authors: Rafael Alonso; María-Teresa Cedena; Sandy Wong; Nina Shah; Rafael Ríos-Tamayo; José M Moraleda; Javier López-Jiménez; Cristina García; Natasha Bahri; Antonio Valeri; Ricardo Sánchez; Luis Collado-Yurrita; Thomas Martin; Jeffrey Wolf; Juan-José Lahuerta; Joaquín Martínez-López Journal: Blood Adv Date: 2020-05-26
Authors: Meletios A Dimopoulos; Andrzej J Jakubowiak; Philip L McCarthy; Robert Z Orlowski; Michel Attal; Joan Bladé; Hartmut Goldschmidt; Katja C Weisel; Karthik Ramasamy; Sonja Zweegman; Andrew Spencer; Jeffrey S Y Huang; Jin Lu; Kazutaka Sunami; Shinsuke Iida; Wee-Joo Chng; Sarah A Holstein; Alberto Rocci; Tomas Skacel; Richard Labotka; Antonio Palumbo; Kenneth C Anderson Journal: Blood Cancer J Date: 2020-02-13 Impact factor: 11.037
Authors: Sikander Ailawadhi; Sundar Jagannath; Mohit Narang; Robert M Rifkin; Howard R Terebelo; Kathleen Toomey; Brian G M Durie; James W Hardin; Cristina J Gasparetto; Lynne Wagner; James L Omel; Vivek Kumar; Lihua Yue; Amani Kitali; Amit Agarwal; Rafat Abonour Journal: Cancer Med Date: 2019-11-07 Impact factor: 4.452
Authors: Sikander Ailawadhi; Sundar Jagannath; Hans C Lee; Mohit Narang; Robert M Rifkin; Howard R Terebelo; Brian G M Durie; Kathleen Toomey; James W Hardin; Cristina J Gasparetto; Lynne Wagner; James L Omel; Mia He; Lihua Yue; Elizabeth Dawn Flick; Amit Agarwal; Rafat Abonour Journal: Cancer Date: 2020-07-24 Impact factor: 6.860
Authors: Amal AlZahmi; Irena Cenzer; Ulrich Mansmann; Helmut Ostermann; Sebastian Theurich; Tobias Schleinkofer; Karin Berger Journal: PLoS One Date: 2022-07-28 Impact factor: 3.752